Statements (33)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:drug
antidepressant |
gptkbp:approvedBy |
gptkb:FDA
2013 |
gptkbp:ATCCode |
N06AX26
|
gptkbp:CASNumber |
508233-74-7
|
gptkbp:changedNameInUS |
2016
|
gptkbp:chemicalFormula |
C18H22N2S
|
gptkbp:drugClass |
antidepressant
serotonin modulator |
gptkbp:eliminationHalfLife |
66 hours
|
gptkbp:excretion |
kidneys
|
gptkbp:genericName |
gptkb:vortioxetine
|
https://www.w3.org/2000/01/rdf-schema#label |
Trintellix
|
gptkbp:indication |
gptkb:depression
|
gptkbp:legalStatus |
prescription only
|
gptkbp:manufacturer |
gptkb:Takeda
gptkb:Lundbeck |
gptkbp:mechanismOfAction |
serotonin modulator and stimulator
|
gptkbp:metabolism |
liver
|
gptkbp:notRecommendedFor |
bipolar disorder
schizophrenia |
gptkbp:otherName |
gptkb:Brintellix
|
gptkbp:pregnancyCategory |
C (US)
|
gptkbp:routeOfAdministration |
oral
|
gptkbp:sideEffect |
nausea
vomiting constipation dizziness sexual dysfunction |
gptkbp:usedFor |
gptkb:major_depressive_disorder
|
gptkbp:bfsParent |
gptkb:Takeda_(Japan)
|
gptkbp:bfsLayer |
6
|